Elite in Myelodysplastic Syndrome (MDS)

Dr. Aref Al

Hematology
MN - Cancer Hematology
200 1st St SW, 
Rochester, MN 
Offers Telehealth
20 Years of Experience
Elite in Myelodysplastic Syndrome (MDS)
MN - Cancer Hematology
200 1st St SW, 
Rochester, MN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Aref Al is a Hematologist in Rochester, Minnesota. Dr. Al has been practicing medicine for over 20 years and is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 241 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 68 articles and participated in 5 clinical trials in the study of Myelodysplastic Syndrome (MDS).

Specialties
Hematology
Licenses
Internal Medicine in OH
Hospital Affiliations
Mayo Clinic Health System - Albert Lea And Austin
Mayo Clinic Hospital Rochester
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
South Country Health Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

MN - Cancer Hematology
200 1st St SW, Rochester, MN 55905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: February 03, 2026
Intervention Type: Drug
Study Drug: ASTX727
Study Phase: Phase 1/Phase 2
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
Enrollment Status: Terminated
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: Sabatolimab, Venetoclax, Azacitidine
Study Phase: Phase 2
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: March 03, 2025
Intervention Type: Other, Drug
Study Drug: Sapanisertib
Study Phase: Phase 2
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drugs: Cedazuridine, Decitabine
Study Phase: Phase 3
Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
Enrollment Status: Terminated
Publish Date: May 21, 2024
Intervention Type: Drug
Study Drugs: Insulin-Like Growth Factor, Methotrexate
Study Phase: Phase 1/Phase 2
A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed With Acute Myeloid Leukemia and KIT Overexpression
A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed With Acute Myeloid Leukemia and KIT Overexpression
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies
Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies
Enrollment Status: Completed
Publish Date: October 30, 2019
Intervention Type: Other, Drug
Study Phase: Phase 1
A Phase II Study of Combination Midostaurin and Decitabine (MIDDAC) in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia and FLT3 Mutation
A Phase II Study of Combination Midostaurin and Decitabine (MIDDAC) in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia and FLT3 Mutation
Enrollment Status: Terminated
Publish Date: August 07, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
View 8 Less Clinical Trials

237 Total Publications

Acute leukemia of ambiguous lineage with KMT2A-alterations in adults.
Acute leukemia of ambiguous lineage with KMT2A-alterations in adults.
Journal: Leukemia & lymphoma
Published: August 25, 2025
Similar Doctors
Elite in Myelodysplastic Syndrome (MDS)
Dr. Mark Litzow
Hematology
Elite in Myelodysplastic Syndrome (MDS)
Dr. Mark Litzow
Hematology

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances

Mark Litzow is a Hematologist in Rochester, Minnesota. Dr. Litzow is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Graft.

Elite in Myelodysplastic Syndrome (MDS)
Dr. Ayalew Tefferi
Hematology
Elite in Myelodysplastic Syndrome (MDS)
Dr. Ayalew Tefferi
Hematology

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ayalew Tefferi is a Hematologist in Rochester, Minnesota. Dr. Tefferi has been practicing medicine for over 44 years and is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). His top areas of expertise are Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasms (MPN), Splenectomy, and Bone Marrow Transplant.

Elite in Myelodysplastic Syndrome (MDS)
Dr. Naseema Gangat
Hematology
Elite in Myelodysplastic Syndrome (MDS)
Dr. Naseema Gangat
Hematology

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-923-2592
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Naseema Gangat is a Hematologist in Rochester, Minnesota. Dr. Gangat is rated as an Elite provider by MediFind in the treatment of Myelodysplastic Syndrome (MDS). Her top areas of expertise are Essential Thrombocythemia, Leukocytosis, Myeloproliferative Neoplasms (MPN), Bone Marrow Aspiration, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Al's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 10 Advanced Conditions
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile